Oral GLP-1
60 articles on Oral GLP-1, researched and written by the Shotlee Editorial Team from primary sources.
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.
8 min read
GP's Verdict on GLP-1 Tablet Rollout: A Damp Squib?
A UK GP shares his observations on the limited uptake of new GLP-1 weight loss tablets, suggesting patient familiarity with injections and daily dosing challenges may be factors.
8 min read
Oral GLP-1 Drugs May Quiet the Brain's Food Craving Circuit
New research suggests that oral GLP-1 medications, including those used for weight loss and diabetes, might work by influencing the brain's reward pathways, potentially reducing cravings for enjoyable foods and offering insights into treating substance use disorders.
8 min read
Jim Cramer on Eli Lilly Amid Rival's GLP-1 Lawsuit
Jim Cramer weighs in on Eli Lilly's position in the GLP-1 market following a lawsuit from competitor Novo Nordisk, analyzing the situation for investors.
7 min read
Ozempic's Oral Twin: A Needle-Free Weight Loss Revolution Arrives?
A new era in weight management may be dawning as an oral medication, mirroring the efficacy of popular injectables like Ozempic, is poised for approval. This development promises a more accessible and convenient path to weight loss for millions.
7 min read
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
GLP-1s and Menopause: Expert Warns of Accelerated Bone Loss Risk
The collision of rapid weight loss driven by GLP-1 medications like Wegovy and Mounjaro with the natural bone density decline of menopause creates a significant, under-discussed risk for women's skeletal health.
6 min read
Ozempic, Wegovy & Mounjaro: Navigating the GLP-1 Weight Loss Revolution
The global surge in GLP-1 medications for weight loss has sparked a vital conversation in India. While innovators like Nithin Kamath highlight affordability and potential, industry leaders like Kiran Mazumdar-Shaw urge careful consideration. This article delves into the nuances of these transformative drugs, their benefits, the hurdles to long-term adoption, and what they mean for your health journey.
7 min read
Oral Wegovy in the UK: A New Era for Weight Management
Novo Nordisk's groundbreaking approval of an oral GLP-1 for weight management in the UK marks a significant shift, promising wider accessibility and influencing consumer markets.
6 min read
Beyond Ozempic: Why Zepbound Might Be the Heavyweight Champion for Weight Loss
A comprehensive review of the latest clinical data comparing Tirzepatide, Semaglutide, and Liraglutide to determine the most effective option for significant weight reduction.
8 min read
Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation
The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.
7 min read
Wegovy Pill Launch: Why 80% of Patients Are Choosing Oral Semaglutide
The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.
9 min read
Beyond the Needle: New Oral Semaglutide Tech Could Change Weight Loss Forever
Duke University researchers have developed a novel oral delivery system for GLP-1 medications that protects peptides from stomach acid, potentially eliminating the need for injections.
8 min read
Oral GLP-1s Enter the Ring: Early Trends Favoring Foundao Over Wegovy's Pill
The landscape of weight loss treatments is rapidly changing with the introduction of oral GLP-1 medications. This article delves into early adoption trends, comparing the initial uptake of Eli Lilly's oral semaglutide (Foundao) against Novo Nordisk's oral semaglutide (Wegovy's pill), and what these patterns signify for patients and physicians.
6 min read
Beyond Glucose: GLP-1 Therapies Reshape Metabolic Care
The GLP-1 receptor agonist market is experiencing explosive growth, transforming from a diabetes-focused treatment to a cornerstone of comprehensive metabolic care. Discover the key drivers, leading molecules like semaglutide and tirzepatide, and the future outlook.
10 min read
Wegovy Pill Nears EU Approval: A New Era for Obesity Treatment?
Novo Nordisk's groundbreaking Wegovy pill has received a significant recommendation for approval from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This marks a pivotal step towards potentially broadening access to advanced weight management solutions for adults across the European Union.
6 min read
Ozempic, Wegovy, Mounjaro: The GLP-1 Revolution Reshaping Health
The GLP-1 analogue market is experiencing unprecedented growth, transforming from diabetes treatments to comprehensive cardiometabolic solutions. Discover the key drivers, leading medications, and future innovations shaping this dynamic field.
9 min read
The Next Wave of Weight Loss: Understanding Oral GLP-1 Therapy
The landscape of chronic weight management is rapidly evolving beyond injectable GLP-1 medications. New research, including trials for the oral, non-peptide drug orforglipron, suggests a future where highly effective weight loss treatment is as simple as taking a daily pill, potentially overcoming barriers of cost and injection fatigue.
6 min read
GLP-1 Weight Loss Drugs: Eli Lilly's Next-Gen Therapies vs. Novo Nordisk
The race for dominance in the lucrative weight loss drug market is intensifying. While Novo Nordisk's Wegovy has been a pioneer, Eli Lilly is rapidly advancing its pipeline with next-generation therapies poised to challenge the status quo. This article delves into the science, clinical data, and market implications of these groundbreaking treatments.
6 min read
Oral GLP-1s for Weight Loss Maintenance: A New Frontier
A groundbreaking study reveals that switching to an oral GLP-1 medication like orforglipron can help individuals maintain a significant portion of their weight loss achieved with injectable therapies, offering a new avenue for long-term obesity management.
6 min read
Eli Lilly 150 Years: AI, GLP-1 Advances & Future of Weight Loss
Eli Lilly celebrates 150 years with a focus on AI-driven manufacturing, new GLP-1 oral therapies, and expanded neuroscience research, signaling a major shift in pharmaceutical innovation.
8 min read
Amazon Stocks Oral Ozempic Pills: Same-Day Delivery & Pricing Guide
Amazon Pharmacy is expanding access to oral GLP-1 medications like Ozempic and Wegovy through kiosks and same-day delivery. Here is everything you need to know about pricing, logistics, and managing your treatment.
7 min read
GLP-1 Peptides: Understanding Semaglutide, Tirzepatide & More
Discover the science behind GLP-1 peptides, including semaglutide and tirzepatide, and their transformative impact on weight management and metabolic health. Learn about popular medications and how they're changing the landscape of health tracking.
7 min read
GLP-1 Pills for Weight Loss: 8 Key Insights Before You Begin
GLP-1 medications are now available as pills for weight loss, offering a needle-free alternative. This comprehensive guide explores what you need to know before starting, including efficacy, absorption, side effects, and lifestyle considerations.
12 min read
Online GLP-1 Programs: Revolutionizing Medically Supervised Weight Loss
Discover the seismic shift in obesity medicine as online GLP-1 programs leverage telehealth and advanced medications like semaglutide and tirzepatide to provide accessible, medically supervised weight loss solutions.
11 min read
Oral Semaglutide Shows Promise for Pediatric Type 2 Diabetes
Novo Nordisk recently unveiled compelling topline results from the PIONEER TEENS trial, suggesting that oral semaglutide could become the first oral GLP-1 Receptor Agonist (RA) therapy approved for children and adolescents managing Type 2 Diabetes (T2D). This development addresses a significant gap in pediatric endocrinology, offering a potentially more accessible treatment option.
6 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read
Eli Lilly's Q1 Surge: GLP-1 Success Fuels Strong Outlook
Eli Lilly's first quarter of 2026 saw record-breaking performance, largely propelled by the immense demand for its GLP-1 based therapies, Mounjaro and Zepbound. The pharmaceutical giant not only surpassed financial expectations but also significantly raised its full-year outlook, signaling continued growth and innovation in the metabolic disease space.
7 min read
Orforglipron: The New Oral GLP-1 Challenger in Weight Loss
A new daily pill, Orforglipron, is emerging as a significant contender in the weight loss and diabetes management space, offering a potential oral alternative to injectable GLP-1 medications. This article delves into its mechanisms, trial results, and what it means for the future of treatment.
7 min read
Oral GLP-1 Drugs: A New Era for Weight Management in India
The landscape of weight management in India is on the cusp of a significant transformation with the advent of oral GLP-1 therapies. Driven by innovation from Chinese pharmaceutical companies and the impending patent expirations of existing treatments, these new pill-based options promise greater accessibility and affordability, fundamentally reshaping how obesity and metabolic disorders are addressed.
7 min read
New Obesity Pills in the UAE: Navigating Insurance Coverage for Wegovy and Foundayo
As new weight-loss medications enter the UAE market, patients are questioning insurance coverage. We break down the realities of policy, medical necessity, and the future of metabolic health.
2 min read
GLP-1s Don't Work for Everyone: What to Know If Not Seeing Results
Started GLP-1s for weight loss or blood sugar control but seeing no results? New research in Genome Medicine reveals that 10% of people carry PAM gene variants linked to weaker responses. Experts explain genetics, common pitfalls, testing, and effective alternatives to help you succeed.
7 min read
Amazon Launches GLP-1 Weight Loss Program with Fast Access
Amazon is entering the GLP-1 weight loss market with a new program through One Medical and Amazon Pharmacy, promising fast, convenient access to treatments like Wegovy and Zepbound. With pricing as low as $25/month for insured patients and same-day delivery, it positions weight management as a chronic care solution. This could transform how patients access these popular medications.
5 min read
New GLP-1 Playbook for Weight Loss: Shots to Pills Shift
Weight loss treatment is evolving with a new GLP-1 playbook: start with weekly injections for rapid results, then transition to convenient pills for maintenance. Eli Lilly's weight-loss tablet and oral Wegovy promise easier adherence, but with trade-offs in effectiveness and strict dosing rules. Doctors highlight the maintenance challenges that make this shift essential.
6 min read
Wegovy Pill Cost: Get It for $149/Month via WeightWatchers Med+
The new FDA-approved Wegovy pill is now available at just $149 per month for starter doses via WeightWatchers Med+, making GLP-1 weight loss therapy more affordable. This self-pay pricing beats typical injectable costs, but it's limited to 1.5mg and 4mg doses for the first four months. Discover eligibility, comparisons, and how to get started before the offer ends April 15.
5 min read
Eli Lilly Eyes India Rollout for Oral Obesity Drug Orforglipron
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
5 min read
Arecor CEO on FY25 Highlights: AT278 & GLP-1 Progress
Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.
4 min read
Foundayo: Lilly's New Oral GLP-1 Pill for Weight Loss Now in US
Eli Lilly's Foundayo, a groundbreaking once-daily oral GLP-1 pill for weight loss, is now shipping nationwide in the US following FDA approval. Backed by the ATTAIN trials, it delivered an average 27-pound loss at the highest dose. Discover access options, pricing, and what patients need to know.
5 min read
Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect
Eli Lilly has launched Foundayo, its innovative oral GLP-1 drug, directly to U.S. consumers via LillyDirect and major telehealth providers. This once-daily pill offers convenient obesity treatment alongside diet and exercise, with average weight loss of 27 pounds at the highest dose. Now available through Amazon Pharmacy's same-day delivery and more, it's set to challenge Novo's Wegovy dominance.
5 min read
FDA Approves Foundayo Weight Loss Pill, Igniting GLP-1 Showdown
The FDA has approved Foundayo weight loss pill from Eli Lilly on April 1 (ET), introducing a flexible oral GLP-1 option for adults with obesity or weight-related conditions—no food or water restrictions needed. Trial data shows superior weight loss over Rybelsus, averaging 15-20 pounds vs. 8-11 pounds in diabetes patients. This approval sets up a new showdown in the GLP-1 market dominated by injections like Wegovy and Zepbound.
5 min read
Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
5 min read
Wegovy Pill Shows Greater Weight Loss Than Foundayo in Novo Study
Novo Nordisk's latest comparison study claims its Wegovy pill delivers superior weight loss compared to Eli Lilly's newly approved Foundayo tablet. The ORION analysis shows a 3.2 percentage point edge for oral semaglutide, plus lower discontinuation rates due to side effects. As oral GLP-1s compete, discover the key findings and implications for patients.
6 min read
FDA Approves Foundayo: GLP-1 Weight Loss Pill with Fewer Use Restrictions
Eli Lilly's Foundayo, a new GLP-1 weight loss pill, just received FDA approval with key advantages: take it anytime without food or water restrictions. Backed by trials showing 12% body weight loss over 72 weeks, it aims to make obesity treatment more accessible. Compare pricing, side effects, and how it stacks up against Wegovy and injectables.
5 min read
FDA Approves Eli Lilly's Foundayo GLP-1 Pill, Stock Jumps 5%
Eli Lilly's shares surged more than 5% following FDA approval of Foundayo, its new once-daily GLP-1 weight-loss pill that can be taken anytime without food restrictions. This oral option intensifies competition with Novo Nordisk's Wegovy and Ozempic, offering real-world convenience for overweight adults. Discover the trial results, comparisons, and implications for obesity treatment.
4 min read
Kailera Therapeutics Eyes IPO for Obesity Drug Pipeline
Boston-based Kailera Therapeutics is gearing up for an IPO to fuel its obesity drug pipeline, including Phase III GLP-1/GIP agonist ribupatide. Backed by $400M Series A and $600M Series B, the company eyes superior profiles versus blockbusters like Zepbound. Despite $368.7M deficits, topline data looms large.
5 min read
PPH ETF: Drug Pricing Policy & Eli Lilly Risks in 2026
The VanEck Pharmaceutical ETF (PPH) offers broad pharma exposure but faces headwinds from U.S. drug pricing reforms and heavy Eli Lilly weighting. Down 8% in the past month despite 15% one-year gains, PPH's diversification is tested. Key risks include MFN pricing deals and GLP-1 competition.
5 min read
What Is Orforglipron? New Oral Weight-Loss Pill Trial Results
A groundbreaking phase 3 trial shows orforglipron, a new daily oral weight-loss pill, surpassing oral semaglutide in blood sugar control and weight reduction for type 2 diabetes patients. This small-molecule GLP-1 agonist offers advantages over injectables like Ozempic by eliminating needles and refrigeration needs. However, higher gastrointestinal side effects raise questions about long-term tolerability.
5 min read
Eli Lilly's Employer Connect: Unlocking GLP-1 Demand
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
5 min read
Structure's GLP-1 Pill Shows 16% Weight Loss in Phase 2 Trial
Structure Therapeutics announced impressive Phase 2 results for its daily obesity pill, with patients losing about 16% of their body weight compared to placebo after 44 weeks. This positions the company to challenge leaders like Eli Lilly and Novo Nordisk in the race for effective oral GLP-1 therapies. Discover the details and implications for obesity treatment.
4 min read
The Quest for Oral GLP-1s: History and Innovations
For decades, GLP-1 receptor agonists like Ozempic have transformed diabetes and obesity treatment via injections, but patients crave oral options. This guide traces the scientific quest for oral GLP-1s, from early discoveries and Gila monster breakthroughs to Rybelsus challenges and promising algae-based innovations. Understand the barriers and what's next for affordable, pill-based metabolic health.
5 min read
Eli Lilly Invests $3B in China for Next-Gen Oral GLP-1 Drug Production
Eli Lilly is set to invest a substantial $3 billion in China over the next decade to bolster the production of its groundbreaking oral GLP-1 receptor agonist, Orforglipron. This strategic move aims to enhance supply chain capacity for a drug poised to treat type 2 diabetes and obesity.
8 min read
Lindt: GLP-1 Users Eating More Chocolate, Not Less
Contrary to predictions, chocolate sales are surging among GLP-1 weight-loss drug users in the U.S., according to Swiss chocolatier Lindt & Spruengli. An internal analysis reveals these households account for 17.5% of chocolate purchases, with premium varieties rising nearly 17%. This challenges assumptions about appetite suppression from drugs like Ozempic and Mounjaro.
5 min read
Should Employers Cover GLP-1 Drugs? 4 Key Facts to Consider
The launch of the first oral GLP-1 weight-loss drug, Wegovy pill, is sparking renewed interest among employees wary of injections. But as demand surges, employers face tough choices on coverage amid high costs and side effects. This guide outlines 4 key facts from industry experts to inform your benefits strategy.
6 min read
Novo, Hims End GLP-1 Feud, Partner Again on Wegovy
The months-long GLP-1 feud between Novo Nordisk and Hims & Hers Health is over, with a new partnership to sell Wegovy via Hims' telehealth platform expected Monday. Following a recent lawsuit over copycat drugs, shares surged: Hims nearly 40%, Novo 2% after-hours. Analysts call it a surprise positive for expanded market reach.
5 min read
Deutsche Bank Reiterates Buy on Eli Lilly Stock on GLP-1 Growth
Deutsche Bank has reiterated its Buy rating on Eli Lilly stock, highlighting robust GLP-1 prescription growth despite recent dips. With Mounjaro and Zepbound leading, prescriptions rebounded 7% week-over-week, underscoring Lilly's dominance in the diabesity market. Discover the latest data on oral Wegovy and emerging oral GLP-1s like orforglipron.
5 min read
Eli Lilly and Weight-Loss Pharma Now 20% of Irish Exports
Irish pharmaceutical exports hit a record €139bn in 2025, with GLP-1 weight-loss drugs from Eli Lilly and Novo Nordisk driving 20% of total goods exports. Eli Lilly's facilities in Ireland and massive US investments underscore the sector's growth. This boom promises faster access to innovative metabolic treatments for patients.
6 min read
Study Explores Plant-Based Platform for Oral GLP-1 Therapies
A pioneering study led by Henry Daniell at Penn Dental Medicine has engineered lettuce chloroplasts to produce functional exenatide and lixisenatide, offering a plant-based path to oral GLP-1 therapies. This approach addresses key barriers like stomach degradation and high costs, potentially transforming diabetes and obesity treatment. Patients may soon swap weekly injections for simple lettuce-based pills.
6 min read
Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years
Fifteen years before Ozempic sparked the GLP-1 revolution, Zydus Lifesciences in India developed ZYOG1, a promising oral GLP-1 agonist. Showing preclinical benefits for glucose control, weight loss, and a clean safety profile, it earned phase I trial approval in 2010—but was shelved amid high costs. This untold story highlights India's early edge in peptide therapy.
5 min read
Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
5 min read
Eli Lilly's Orforglipron: More Effective GLP-1 Pill for Weight Loss?
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
6 min read